Speakers

Personal Information

Dr. Mandler is a leader in development of active immunotherapies for chronic diseases with > 20 years of collaborative research and management experience. At Tridem he drives the company's R&D-, CMC- and IP strategy and oversees its funding and infrastructure.

Prior to Tridem, his career includes a significant role as CSO at ACCANIS where he was working on mRNA therapeutics in dermal applications. As head of the Neurodegeneration Department at AFFiRiS AG, he was developing new vaccination-based treatments for neurodegenerative diseases, especially focusing on Alzheimer's disease (AD) and synucleinopathies such as Parkinson's disease (PD) and multisystem atrophy (MSA). Dr. Mandler – together with his AFFiRiS team - was responsible for the selection of the first two peptide-based vaccines for PD and MSA ever tested in humans.